Close Menu

NEW YORK (360Dx) – German diagnostics firm Sphingotec is using proceeds from a €20 million ($23 million) funding round announced last week to commercialize automated point-of-care versions of its biomarker tests proenkephalin (penKid) and adrenomedullin (bio-ADM).

The tests are intended for monitoring kidney function (penKid) and endothelial dysfunction (bio-ADM) to identify intensive care and emergency department patients at risk of heart failure.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.